Income Statement (LYELL/IMMUNOPHARMA)

Technical Analysis Historical Data Financials News & Analysis

LYELL/IMMUNOPHARMA NEWS

HC Wainwright Reaffirms “Neutral” Rating for Lyell Immunopharma (NASDAQ:LYEL) By MarketBeat - 2 months ago

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. Th… [+2687 chars]...

Read more
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 By Site Author - 2 months ago

  • Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive … [+29349 chars]...

    Read more
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight By DelveInsight - 2 months ago

New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight T-cell recep… [+15407 chars]...

Read more
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain By DelveInsight - 2 months ago

New York, USA, March 05, 2025 (GLOBE NEWSWIRE) -- CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the D… [+15507 chars]...

Read more
Top Stock
CurrencyPrice Chg
BA 		205.82 -0.42
-0.2%
CVX 		142.1 -0.16
-0.11%
CAT 		353.58 3.77
1.08%
INTC 		21.66 0.11
0.51%
MSFT 		454.27 1.14
0.25%
DIS 		113.42 1.2
1.07%
DOW 		30.19 0.29
0.97%
CSCO 		63.62 -0.64
-1%
GS 		619.03 3.13
0.51%